152 related articles for article (PubMed ID: 37899244)
1. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
2. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
3. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Kondo T; Nagamura-Inoue T; Tojo A; Nagamura F; Uchida N; Nakamae H; Fukuda T; Mori T; Yano S; Kurokawa M; Ueno H; Kanamori H; Hashimoto H; Onizuka M; Takanashi M; Ichinohe T; Atsuta Y; Ohashi K
Am J Hematol; 2017 Sep; 92(9):902-908. PubMed ID: 28543934
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.
Jiang H; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang Q; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Wang JZ; Wang FR; Qin YZ; Lai YY; Huang XJ
Bone Marrow Transplant; 2014 Sep; 49(9):1146-54. PubMed ID: 25046218
[TBL] [Abstract][Full Text] [Related]
7. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
8. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y; Sbianchi G; Gras L; Koster L; Apperley J; Byrne J; Salmenniemi U; Sengeloev H; Aljurf M; Helbig G; Kinsella F; Choi G; Reményi P; Snowden JA; Robin M; Lenhoff S; Mielke S; Passweg J; Broers AEC; Kröger N; Yegin ZA; Tan SM; Hayden PJ; McLornan DP; Yakoub-Agha I;
Am J Hematol; 2023 Jan; 98(1):112-121. PubMed ID: 36266607
[TBL] [Abstract][Full Text] [Related]
10. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation.
Suttorp M; Millot F
Hematology Am Soc Hematol Educ Program; 2010; 2010():368-76. PubMed ID: 21239821
[TBL] [Abstract][Full Text] [Related]
12. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy.
Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Todorić-Zivanović B; Ostojić G; Tatomirović Z; Marjanović S; Malesević M
Vojnosanit Pregl; 2012 Jan; 69(1):37-42. PubMed ID: 22397295
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
15. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
16. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
Varda-Bloom N; Danylesko I; Shouval R; Eldror S; Lev A; Davidson J; Rosenthal E; Volchek Y; Shem-Tov N; Yerushalmi R; Shimoni A; Somech R; Nagler A
Oncotarget; 2017 Jan; 8(1):418-429. PubMed ID: 27880933
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
Jain N; van Besien K
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1025-48, vi. PubMed ID: 22054733
[TBL] [Abstract][Full Text] [Related]
18. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
20. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
